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Background: Tinnitus and dizziness are frequent in old age and often seen as concomitant symptoms 
in patients with dementia. In earlier clinical trials, Ginkgo biloba extract EGb 761® was found to alleviate 
tinnitus and dizziness in elderly patients. Consequently, a meta-analysis was conducted to evaluate the 
effects of EGb 761® at a daily dose of 240 mg on tinnitus and dizziness associated with dementia.
Methods: Randomized, placebo-controlled clinical trials of G. biloba extract EGb 761® iden-
tified by a systematic database search were included in a meta-analysis if they met all of the 
following selection criteria: 1) diagnosis of dementia according to generally accepted criteria, 
2) treatment period of at least 20 weeks, 3) outcome measures covering at least two of the three 
conventional domains of assessment, 4) presence and severity of dizziness and tinnitus were 
assessed, and 5) assessment was done before and after randomized treatment.
Results: Five trials that met the inclusion criteria were included in the meta-analysis. The risk 
of bias was judged as low, with Jadad scores of 3 and 5. In all trials, 11-point box scales were 
used to assess the severity of tinnitus and dizziness. Overall, EGb 761® was superior to placebo, 
with weighted mean differences for change from baseline, calculated in meta-analyses using 
random effects models, of -1.06 (95% CI: -1.77, -0.36) for tinnitus (p = 0.003) and -0.77 
(95% CI: -1.44, -0.09) for dizziness (p = 0.03).
Conclusion: Our findings support the notion that EGb 761® is also effective in alleviating 
concomitant neurosensory symptoms in patients with dementia.
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Introduction
Neurosensory symptoms, such as tinnitus and dizziness, are frequently observed in 
elderly people and even more so in patients with dementia. Five-year and 10-year 
incidence rates of 18.0% and 12.7% were reported for tinnitus from the Blue Moun-
tains Hearing Study and the Beaver Dam Epidemiology of Hearing Loss Study, 
respectively.1,2 Epidemiological studies have found an increase in the prevalence of 
tinnitus as a function of age.3 Jahn et al reported 1-year prevalence rates for significant 
dizziness of 20% in persons older than 60 years, 30% in those older than 70 years, 
and 50% in those older than 80 years.4 In elderly patients with dementia, we found 
prevalence rates between 13% and 52% for tinnitus and between 14.2% and 77.5% for 
dizziness in five clinical trials.5–9 Age-related hearing loss is likely to account for higher 
rates of tinnitus in the elderly and may even contribute to cognitive decline and the 
development of Alzheimer’s disease (AD) and other dementias.10–13 In a case-control 
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study of elderly patients with neurological disorders, those 
with dementia had a particularly high rate of falls (60% in 1 
year), which may indicate a higher prevalence of dizziness 
and impaired equilibrium control.14
Given the high comorbidity of tinnitus and dizziness in 
dementia and the findings from earlier studies in which Ginkgo 
biloba extract EGb 761® (Dr Willmar Schwabe GmbH & Co. 
KG, Karlsruhe, Germany) alleviated tinnitus and dizziness or 
vertigo,15,16 measures of tinnitus and dizziness were included in 
recent clinical trials of EGb 761® in patients with dementia.
When considering why G. biloba extract EGb 761® may 
alleviate tinnitus, dizziness, or vertigo in patients with demen-
tia, the pathomechanisms underlying these symptoms should 
be taken into account. Neurons of the central vestibular and 
auditory systems, cochlear hair cells, and vestibular sensory 
cells have a high energy demand in order to maintain and 
continuously restore their transmembrane electrical potential. 
Impaired mitochondrial function and impaired perfusion are 
thought to contribute to both cochlear and vestibular dysfunc-
tion and sensory cell degeneration.17 EGb 761® improves inner 
ear and cerebral blood flow by decreasing blood viscosity; it 
also improves mitochondrial function and energy metabolism, 
which altogether may play a role in improving inner ear and 
brain function in elderly people with dementia who often 
have vascular disorders and compromised mitochondrial 
function.18–20 The antiapoptotic and neuroprotective proper-
ties of EGb 761® may inhibit aging-related loss of cochlear 
and vestibular sensory cells,21–24 which may play a role in 
tinnitus and vertigo.25,26 Coping with the distress of tinnitus 
as well as compensating for vestibular dysfunction involves 
both learning and neuroplasticity. EGb 761® enhances neu-
roplasticity, improves learning, and accelerates vestibular 
compensation.18,27,28 Tinnitus is likely to cause distress and 
anxiety, while dizziness often causes unsteadiness and fear of 
falling. Due to anxiolytic effects and by attenuating the activa-
tion of the stress axis, EGb 761® may decrease the distress in 
both conditions.18,29,30 By improving the speed of information 
processing, it may improve gait and reduce unsteadiness.18
Here, we present a meta-analysis of the trials that used rat-
ing scales for the assessment of presence and severity of tinnitus 
and dizziness. The question addressed by this meta-analysis was 
whether, taking into account all available evidence, EGb 761® 
treatment was superior to placebo in alleviating tinnitus or diz-
ziness or both in patients with dementia who had one or both of 
these neurosensory symptoms at pre-treatment examination.
Materials and methods
In 2014, Gauthier and Schlaefke published a systematic 
review and meta-analysis of randomized, placebo-controlled, 
double-blind clinical trials of G. biloba extract EGb 761® 
in patients with mild to moderate dementia (AD, vascular 
dementia [VaD], mixed dementia, ie, AD with cerebrovas-
cular disease [CVD]).31 The search strategy is described in 
detail in their original paper.31 Our aim was to provide an 
update on studies until October 2017. We did not identify 
any further relevant studies. Briefly, PubMed, including 
and excluding MedLine (from beginning to October 2017), 
EMBASE (from January 2006 to October 2017), and PAS-
CAL (from beginning to end of 2015, no further update of 
PASCAL existed beyond this date) were searched using 
the following search terms (with * characterizing a wild-
card, and the items AND and OR being used as Boolean 
functions): (ginkg* OR gingk*) AND clinical trial[pt] for 
PubMed including MedLine, ((ginkg* OR gingk*) NOT 
medline[sb]) AND (clinical* OR trial OR randomized) for 
PubMed excluding Medline, (GINKGO OR GINGKO) 
AND (HUMAN/CT OR HOMME/CTFR) for PASCAL, 
and (ginkgo or gingko) AND CT=(CLINICAL TRIAL; 
CLINICAL STUDY; DOUBLE BLIND PROCEDURE) 
AND py.2005 for EMBASE. The papers retrieved were 
assessed for eligibility by two scientists independently and 
trials were selected for the review, if 1) the diagnoses were 
established in accordance with generally accepted diagnostic 
criteria, 2) the treatment periods were at least 20 weeks, and 
3) outcome measures covered at least two of the three con-
ventional domains (cognition, global judgment, activities of 
daily living). For the current meta-analysis, we applied two 
additional inclusion criteria, requiring that 4) the presence 
and severity of tinnitus or dizziness or both were assessed 
and 5) assessment was done before the start and after the end 
of randomized treatment. Five of the seven trials included 
in the meta-analysis by Gauthier and Schlaefke met these 
additional criteria.5–9 All trials were sponsored by Dr Willmar 
Schwabe GmbH & Co. KG, Karlsruhe, Germany. The risk 
of bias was low for all five trials, with Jadad scores of 3 and 
5 (Table 1).32
In all five trials, 11-point box scales were used to assess 
the presence and severity of tinnitus and dizziness. The 
11-point box scale is a type of visual analog scale (VAS) 
consisting of 11 adjacent boxes which contain ascending 
numbers from 0 to 10 and descriptors for the extremes only, 
thus providing a distinct number of possible responses in a 
single dimension. Such types of 11-point VASs are often used 
as measures for pain,33,34 and have also been found useful for 
the assessment of other unpleasant and distressing symptoms, 
such as dizziness35 or tinnitus.33,36,37 In the studies reviewed 
here, 11-point box scales for tinnitus and dizziness were 
administered with the extreme ends indicating “no tinnitus 
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at all” (0) and “extremely severe tinnitus” (10) or “no dizzi-
ness at all” (0) and “extremely severe dizziness” (10).
One study enrolled patients exclusively with AD,5 while 
all other studies also accepted patients with VaD or AD 
with CVD.6–9 In one study, two different doses of EGb 761® 
(240 mg or 120 mg) and placebo were compared;5 however, 
the patients treated with 120 mg of EGb 761® were excluded 
from the present meta-analysis. In all other studies, patients 
received either 240 mg of EGb 761® or placebo.
For each study, EGb 761® and placebo treatment were 
compared with regard to mean differences between baseline 
and end of treatment on both 11-point box scales for tinnitus 
and dizziness. These calculations, conducted with SAS 
version 9.3, were based on individual patient data, which 
were provided by Dr Willmar Schwabe GmbH & Co. KG. 
Based on the study-specific mean differences, weighted mean 
differences (and corresponding forest plots) were calculated 
using meta-analytical models to compare EGb 761® and 
placebo treatments by Review Manager (version 5). Due to 
the somewhat different inclusion criteria and design of the 
trial conducted by Schneider et al5 compared to the other 
four trials, which were similarly designed, a random effects 
model was chosen for the analysis and a fixed effects model 
as a sensitivity analysis. Only data from patients who had 
tinnitus or dizziness at baseline (baseline scores .0 on the 
respective 11-point box scale) were included in the respec-
tive meta-analyses. Missing data were replaced by the last-
observation-carried-forward method.
Results
In the five studies, a total of 1,972 patients, aged 50–98 years, 
were randomly assigned to receive EGb 761® at a daily 
dose of 240 mg or placebo. The treatment periods were 
22–26 weeks. The full analysis comprised a total of 1,942 
patients, of whom 904 were diagnosed with probable AD, 
374 had probable VaD, and 664 had mixed dementia. Study 
characteristics and demographics are provided in Table 1. 
Dementia-related baseline scores and outcomes are provided 
in detail by Gauthier and Schlaefke.31
Altogether, 773 patients had tinnitus at baseline (EGb 
761®, 372; placebo, 401). In the individual studies, preva-
lence of tinnitus ranged between 13% and 52%; the average 
severity ratings varied between ~2.7 and 4.0. The baseline 
scores for the 11-point box scale related to tinnitus are 
provided in Table 2.
A total of 1,040 patients reported dizziness at baseline 
(EGb 761®, 528; placebo, 512). Prevalence in the individual 
studies ranged from 13% to 77%; the average severity ratings 
varied between 2.5 and 4.3. The baseline scores for the 
11-point box scale related to dizziness are shown in Table 3.
A mean reduction in tinnitus severity for the EGb 761®-
treated patients compared to placebo was observed in all five 
trials. The difference in favor of EGb 761® was statistically 
meaningful in four trials. Overall, there was a weighted mean 
difference of -1.06 (95% CI: -1.77, -0.36) favoring EGb 
761® at p = 0.003 (Figure 1). This was similar to the result 
of the sensitivity analysis by the fixed effects model: -0.97 
(95% CI: -1.16, -0.78; p , 0.001). Considering that the 
average severity of tinnitus was between 2.7 and 4.0 at 
baseline,5,6 the weighted mean difference corresponds to an 
improvement over placebo effects by 27%–40% of baseline 
severity in the single studies.
A greater reduction in dizziness was observed for the EGb 
761®-treated patients in four of the five trials comprising 96% of 
Table 1 Study characteristics and demographics (mean ± standard deviation for age)
Study Jadad 
score
Treatment 
duration 
(weeks)
EGb 761® Placebo
Na % Female Age 
(years)
N % Female Age 
(years)
Schneider et al, 20055 3 26 170 56 78 ± 7 174 52 77 ± 7
Napryeyenko et al, 20076 5 22 198 72 65 ± 8 197 72 63 ± 8
Nikolova et al, 20139 3 22 196 57 69 ± 8 201 60 69 ± 8
Ihl et al, 20117 5 24 202 69 65 ± 10 202 66 65 ± 9
Herrschaft et al, 20128 5 24 200 70 65 ± 9 202 69 65 ± 9
Note: aFull analysis set.
Abbreviation: N, number of patients.
Table 2 eleven-point box scale baseline scores for patients with 
tinnitus (mean, standard deviation)
Study EGb 761® Placebo
N Score N Score
Schneider et al, 20055 19 2.84 ± 1.80 24 2.54 ± 1.82
Napryeyenko et al, 20076 102 4.03 ± 1.61 104 3.89 ± 1.45
Nikolova et al, 20139 64 3.53 ± 1.94 72 2.94 ± 1.81
Ihl et al, 20117 90 2.92 ± 1.52 107 2.92 ± 1.54
Herrschaft et al, 20128 97 2.90 ± 1.64 94 3.02 ± 1.41
Abbreviation: N, number of patients.
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all patients included in the meta-analysis. The differences in 
favor of EGb 761® were statistically meaningful in three trials 
comprising 80% of all patients. Overall, there was a weighted 
mean difference of -0.77 (95% CI: -1.44, -0.09) favoring EGb 
761® at p = 0.03 (Figure 2) and similar to the fixed effects model 
calculated as a sensitivity analysis: -0.98 (95% CI: -1.15, –0.81; 
p , 0.001). The average severity of dizziness at baseline was 
between 2.5 and 4.3.5,6 Therefore, the weighted mean difference 
corresponds to an improvement over placebo effects of between 
18% and 31% of baseline severity in the four larger trials.
Discussion
In our meta-analysis, we included five randomized, placebo-
controlled clinical trials of G. biloba extract EGb 761® in 
patients with mild to moderate dementia. Using 11-point 
box scales to assess the presence and severity of tinnitus 
and dizziness, we found that a considerable proportion of 
the patients enrolled for their diagnoses of dementia, and not 
for tinnitus or dizziness, had such neurosensory symptoms. 
On average, these symptoms were mild to moderate at base-
line. Overall, we found EGb 761® to be clearly superior to 
placebo in alleviating both tinnitus and dizziness. This is 
in line with the results of earlier trials in patients with tin-
nitus or vertigo,15,16 in whom these neurosensory symptoms 
were the main complaints. It is also in line with conclusions 
from systematic reviews that found EGb 761®, but not other 
G. biloba extracts, to be effective in the treatment of tinnitus 
and vertigo.15,16 EGb 761® is a defined extract of G. biloba 
leaves that is obtained by a proprietary multi-step extraction 
procedure during which pharmacodynamically active mol-
ecules are enriched and harmful compounds are removed. 
EGb 761® is adjusted to 22.0%–27.0% ginkgo flavonoids 
calculated as ginkgo flavone glycosides and 2.0%–7.0% ter-
pene lactones consisting of 2.8%–3.4% ginkgolides A, B, C 
and 2.6%–3.2% bilobalide and contains less than 5 ppm 
ginkgolic acids. High batch-to-batch consistency, which 
is a prerequisite for the generalization of study results to 
daily clinical practice, has been demonstrated. Extracts that 
result from different productive processes are inherently 
different in composition, and in pharmacodynamic and 
clinical activity.18 Our literature search did not identify any 
randomized, placebo-controlled clinical trials of any other 
Ginkgo extract in patients with dementia in which effects on 
tinnitus or dizziness were evaluated.
The clinical relevance of the effects is difficult to assess. 
Reductions in tinnitus severity by 27%–40% over and above 
the placebo effect may represent clinically relevant effect 
sizes. The effects on dizziness are less pronounced, but may 
still be clinically relevant in the given population of elderly 
people with ischemic and neurodegenerative CNS changes, 
who are particularly prone to falling. When evaluating 
clinical relevance in this context, the fact that the patients 
had mild to moderate dementia has to be kept in mind. Tin-
nitus may contribute to cognitive decline in dementia.12,13 
Both tinnitus and dizziness cause anxiety, fear (fear of 
enduring annoyance and fear of falling, respectively), and 
distress.1,4,38,39 Tinnitus often leads to sleep disturbances,1,39 
thus adding to the burden of night-time disturbances fre-
quently experienced by patients with dementia.40 Stress-
induced activation of the hypothalamic–pituitary–adrenal 
axis (the so-called stress axis) tends to further compromise 
cognitive functioning in patients with cognitive impairment.41 
Focusing on and being distracted by tinnitus may addition-
ally impair attention and processing speed, ie, the cognitive 
Table 3 eleven-point box scale baseline scores for patients with 
dizziness (mean, standard deviation)
Study EGb 761® Placebo
N Score N Score
Schneider et al, 20055 24 2.29 ± 1.23 22 2.64 ± 1.97
Napryeyenko et al, 20076 149 4.37 ± 1.42 157 4.22 ± 1.43
Nikolova et al, 20139 88 3.52 ± 1.84 71 3.18 ± 2.04
Ihl et al, 20117 136 3.04 ± 1.54 139 3.02 ± 1.33
Herrschaft et al, 20128 131 3.10 ± 1.37 123 3.01 ± 1.39
Abbreviation: N, number of patients.
+HWHURJHQHLW\τ χ GI S, 7HVWIRURYHUDOOHIIHFW= S 
±±±±±
0HDQ
±±±±±
0HDQ

6'


7RWDO


7RWDO(*E
 3ODFHER


:HLJKW
±±±±±±±±±±±±±±
±±±
0HDQGLIIHUHQFH,9UDQGRP&, 0HDQGLIIHUHQFH,9UDQGRP&,
± ± )DYRUV(*E )DYRUVSODFHER 

6'
7RWDO&,
6FKQHLGHUHWDO
6WXG\RUVXEJURXS
1DSU\H\HQNRHWDO1LNRORYDHWDO,KOHWDO+HUUVFKDIWHWDO
Figure 1 Meta-analysis of changes in tinnitus severity across five clinical trials using the 11-point box scale (weighted mean differences [95% CI] from random effects model).
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abilities already compromised in patients with dementia.39 
Dizziness and fear of falling often lead to reduced physical 
activity, decreased participation in social life, disability, and 
frailty.42 Physical activity is not only necessary to maintain 
muscle mass and postural control,43,44 it is also closely cor-
related with cognitive performance in elderly people with 
and without cognitive impairment.45–47 Moreover, dizziness 
is not only associated with fear of falling, it also increases 
the risk of falling and the incidence of falling-related injuries, 
such as hip fractures.4 However, hospitalization and major 
surgery increase the risk of confusion and delirium and may 
accelerate cognitive decline in patients with dementia.48
Our meta-analysis has some limitations related to the 
studies included. First, the symptom ratings were done by 
patients with dementia, which may cast doubts on their reli-
ability. However, patients with mild to moderate dementia are 
still able to understand questions about ringing in the ears and 
dizziness, when asked in simple language. They may have 
problems remembering the intensity of tinnitus or dizziness at 
an earlier point in time, but the 11-point box scales ask about 
the current severity, and not about changes. Rating errors due 
to cognitive problems may possibly increase scatter, but does 
not build a consistent pattern of treatment benefits across the 
studies as found in the present meta-analysis.
Second, no examinations of auditory or vestibular func-
tions were performed, and disabilities related to tinnitus 
and dizziness were not assessed within the studies. As a 
consequence, it is not known to what extent alleviation 
of tinnitus and/or dizziness may have contributed to the 
improvement in everyday functioning and quality of life. 
After all the examinations required by current guidelines for 
clinical trials in dementia have been performed, the patients 
are usually too exhausted to undergo further examinations 
during the same visit. Investigators were free to perform all 
examinations required for medical reasons, but any findings 
not related to the studies were not documented in the case 
record forms. As a result, to what extent dizziness was related 
to vestibular vertigo or to non-vestibular disorders remains 
unknown. Yet, the dizziness-related problems in patients with 
dementia are largely the same. It is possible, however, that 
different proportions of patients with vestibular vertigo and 
non-vestibular dizziness contributed to the heterogeneity of 
the outcomes related to dizziness.
Third, average baseline scores for tinnitus and dizziness 
were around 3, ie, about one-third of the range of the scales, 
in most trials. As a consequence, the relative effect sizes may 
lead to an overestimation of their clinical relevance. On the 
other hand, floor effects cannot be excluded, so that the real 
therapeutic potential of the drug could be underestimated.
In general, patients complaining of tinnitus or dizziness 
should be examined for causes and contributors that are 
amenable to specific treatments, irrespective of whether or 
not they have dementia. Assessment of auditory or vestibular 
function might provide additional information about the 
underlying causes. However, in many patients the causes of 
neurosensory symptoms remain unclear, and even if known, 
there are often no causal or cause-specific treatments. As out-
lined earlier, EGb 761® interferes with a number of mecha-
nisms that seem to contribute to dysfunction and degenerative 
processes in the inner ear and cerebral structures.
Conclusion
G. biloba extract EGb 761®, at daily doses of 240 mg, allevi-
ated both tinnitus and dizziness in patients with dementia, 
ie, in patients who are particularly vulnerable to such dis-
turbances. This should be taken into account when choosing 
an appropriate treatment for patients with dementia and 
neurosensory symptoms.
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Figure 2 Meta-analysis of changes in dizziness severity across five clinical trials using the 11-point box scale (weighted mean differences [95% CI] from random effects model).
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